That's a great question.
Access, affordability and cost structures are major conversations for this country to have, and for policy-makers such as you to be informed on and thinking about. Cell and gene therapies will be revolutionary for our health care system. The way that we think about them, where the costs will come up front rather than over a lifetime, is different from how our health care system thinks about these drugs and therapies at this point. We need to reconceptualize that.
We need to understand the values that Canadians have around cell and gene therapies and how to adopt them. We need to think about the tools that decision-makers need to be able to make decisions around what will be adopted by our health care system. This will take a number of years and all sorts of different voices at the table, from industry to academia and regulators.
The Stem Cell Network in our next strategic plan is proposing to do exactly that and bring those parties together so that by the time we get to 2030, we have the path forward in place. We'll know how to think about access and affordability.
The science is going to come. It's up to governments and the rest of us to think about how we make that sure these technologies are adopted and not lost to others.